Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CKD 712

Next Previous
Drug Profile

CKD 712

Alternative Names: CKD-712

Latest Information Update: 04 Nov 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chong Kun Dang
  • Class Alkaloids; Isoquinolines
  • Mechanism of Action I-kappa B kinase inhibitors; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Sepsis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Sepsis in South Korea (IV)
  • 13 May 2010 Phase I development is ongoing in South Korea
  • 03 May 2010 CKD 712 is available for licensing worldwide (http://210.92.140.4/research.htm)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top